At a Glance
Yes. With sustained prevention, coronary disease can improve in meaningful ways. Plaque burden may decrease modestly, plaque composition can shift toward greater stability, blood flow can improve, and the risk of future events can fall.
The change in the narrowing itself is usually small. The change in risk can be large, because treatment can stabilize the lipid-rich plaques that disproportionately trigger heart attacks.
The most consistent driver of plaque regression and stabilization is sustained lowering of atherogenic ApoB-containing particles. LDL cholesterol is the usual treatment target and a practical proxy in many people; ApoB can add information when the two are discordant.
Blood pressure, diabetes, smoking, physical activity, diet, sleep, and other parts of daily life help determine whether plaque keeps growing even when cholesterol looks good.
A stress test can improve without the blockage changing at all. In some people, collateral circulation and small-vessel function improve, while treatment can also lower the heart’s oxygen demand.
A rising calcium score on a statin does not necessarily mean treatment is failing. Calcium scoring is not a reliable report card for treatment response.
Improvement needs upkeep. For most people with established coronary atherosclerosis, prevention is long-term and should be reviewed and adjusted over time.
“Can my blockages get better?”
I hear this question in almost every conversation that follows a cardiac catheterization, a CT angiogram, or an abnormal stress test. Sometimes it comes out as a whisper. Sometimes it comes with a printout from the internet promising that a particular diet “melts plaque away.” Most often, it comes with a quieter question underneath: Is this damage permanent, or is there still something I can do?
The honest answer is yes: with sustained prevention, coronary disease can improve in meaningful ways. But the change is usually not a dramatic disappearance of a blockage. It is more often a shift toward plaque that is smaller, less lipid-rich, more stable, and less likely to trigger a heart attack.
Regression is possible, but it is usually partial—not a cure, not a reason to stop treatment, and not something that can be reliably demonstrated by repeating scans until a better number appears. Once you understand what actually changes in the artery, the answer becomes more hopeful, not less.
A note about symptoms: Do not use this article to interpret new or worsening chest pressure, shortness of breath, sweating, fainting, pain in the jaw, arm, back, or upper abdomen, or a sudden decline in exercise tolerance. Those symptoms need prompt clinical assessment. If they are severe, persistent, or concerning, call emergency services.
Plaque is not a clog in a pipe
Most of us imagine a coronary blockage the way a plumber would: grease building up inside a pipe until the water cannot get through. That picture is intuitive, and it is wrong in ways that matter.
Plaque does not sit on the inside surface of the artery. It grows within the wall. The closer image is a blister. A pocket of cholesterol, inflammatory cells, and dead-cell debris sits under a thin cap of tissue, tucked inside the artery wall itself.
For years, the artery makes room for that blister by bulging outward. In a classic autopsy study of the left main coronary artery in 136 hearts, the channel for blood did not narrow until plaque filled roughly 40% of the artery’s cross-section.¹ In other words, you can carry a substantial amount of plaque with a channel that still looks nearly normal on an angiogram.
This matters because many type 1 heart attacks occur when a lipid-rich plaque ruptures or erodes and a clot forms on top of it. In studies of people who had angiography before a later heart attack, many future culprit lesions had appeared only mild or moderate on the earlier angiogram.² A heart attack is often not the result of a slow clog finally sealing shut.
Other causes of myocardial infarction exist, including supply-demand mismatch, spontaneous coronary artery dissection, coronary spasm, and embolic disease. New symptoms always require clinical evaluation. But for atherosclerotic coronary disease, keep the blister in mind. It explains almost everything that follows.
What “regression” actually means
When cardiologists talk about regression, we can mean five different things. They are measured with different tools, and they change on different timelines:
What may improveWhat it can showWhat it cannot prove by itselfThe channel is widerAn angiogram can show the lumen, or channel, of a larger coronary arteryTotal plaque burden, plaque composition, or small-vessel functionThere is less plaque in the wallIntravascular ultrasound, specialized intracoronary imaging, or detailed CT plaque assessment can estimate plaque burdenThat a particular person will never have a future eventThe plaque is saferSome imaging can show changes in plaque volume and features associated with stabilityThat every dangerous plaque has been identified or eliminatedThe heart muscle gets more blood under stressNuclear stress testing, PET, and other stress imaging can show ischemia or perfusion reserveThat a particular blockage has shrunkThere are fewer events and better daily functionSymptoms, exercise capacity, hospitalizations, heart attacks, procedures, and survival show what matters mostWhich individual plaque changed, or exactly why
These layers often move in the same direction, but not always, and not at the same speed. A great deal of confusion about “reversing heart disease” comes from mixing them up.
Yes, regression has been documented, many times
Even before modern cholesterol medicines, repeat angiograms showed that coronary disease is not a one-way street. In older serial-angiography studies, untreated coronary disease more often progressed than regressed. Spontaneous angiographic improvement was uncommon.³
Treatment changed those odds. In the Familial Atherosclerosis Treatment Study (FATS), men with high ApoB and established coronary disease received intensive lipid-lowering therapy for two and a half years. Intensive lipid lowering increased the frequency of angiographic regression and was associated with fewer coronary events than conventional treatment.⁴
The POSCH trial followed survivors of heart attack after a surgical procedure that permanently lowered cholesterol. On repeat angiography over ten years, definite progression was less common and regression more common in the treated group; coronary death plus nonfatal heart attack also fell.⁵
These are important findings, but the main lesson is not that every blockage disappears. It is that atherosclerosis can be modified over time.
The surprising part: the channel barely moves
If regression is real, why does a follow-up angiogram not always look dramatically better?
Because the average change in the channel is often small. Yet coronary events can fall substantially.⁶
How can a change that small produce a benefit that large? The answer goes back to the blister. Intensive lipid lowering appears to work not only by reducing plaque burden, but also by changing plaque features linked to instability. These vulnerable features are disproportionately represented among plaques that trigger acute coronary events.
The channel may look almost the same, but what is inside the wall may have changed. The lipid core can shrink. The cap over plaque can become thicker. The plaque can become more fibrotic and less prone to rupture.
Modern imaging lets us watch parts of this happen. In PACMAN-AMI, patients who had just had a heart attack were treated with a PCSK9 inhibitor on top of a high-intensity statin. Over one year, adding alirocumab produced greater regression of nonculprit plaque and greater thickening of the fibrous cap than statin treatment alone.⁷
That is what “better” often looks like: not an artery restored to adolescence, but plaque that is less likely to rupture.
What makes plaque grow
If you want plaque to stop growing, it helps to know what feeds it.
ApoB-containing particles. ApoB-containing particles—including LDL and cholesterol-rich remnant particles—can enter and become trapped in the artery wall. Over years, that retained cholesterol helps build and sustain plaque. LDL-C and ApoB usually move together, but ApoB can be particularly useful when triglycerides are elevated or metabolic health is impaired and the two measurements do not match.
Blood pressure. In an imaging analysis of patients with coronary disease, lower achieved blood pressure was associated with less plaque progression over two years.⁸ This does not establish one universal blood-pressure target for everyone, but it reinforces that blood pressure is part of atherosclerosis treatment, not a separate issue.
Diabetes and insulin resistance. People with diabetes often have faster plaque progression. In pooled intravascular-ultrasound studies, diabetes remained associated with less favorable plaque change even when LDL lowering was substantial.⁹
Smoking. Smoking injures the artery lining and makes clots more likely. Smoking is associated with atherosclerotic cardiovascular disease, and cardiovascular risk falls after quitting.¹⁰
Other exposures and conditions. Some prescribed therapies, supplements, hormones, chronic inflammatory diseases, kidney disease, sleep disorders, and metabolic conditions can influence cardiovascular risk. For example, in one trial of older men with low testosterone, testosterone therapy increased noncalcified coronary plaque volume compared with placebo.¹¹ The study measured CT plaque over one year and was not designed to determine whether testosterone changed the risk of heart attack, stroke, or death. That finding does not mean that anyone should stop prescribed hormone therapy because of this article. It means all medications, hormones, supplements, and exposures deserve a thoughtful, individualized review when plaque is progressing despite otherwise good control.
Here is the finding I share with patients who have already worked hard to lower their LDL. Even when LDL cholesterol is lowered to very low levels, some people still show plaque progression on serial imaging. Diabetes, blood pressure, and other residual-risk features can help identify people whose plaque is more likely to continue progressing.¹² Cholesterol matters enormously, but it is not the whole story.
What helps plaque regress
Lower atherogenic particles, and keep them low. This is the single most consistent lever across imaging studies. In ASTEROID, high-intensity statin therapy brought average LDL-C to about 61 mg/dL, and many participants demonstrated plaque regression over two years.¹³ In GLAGOV, adding a PCSK9 inhibitor to a statin lowered LDL-C substantially further, and a larger proportion of participants had regression on intravascular ultrasound.¹⁴
Move your body, as if it were a prescription. In an older randomized German study of patients with coronary disease, greater leisure-time activity was associated with less progression and, at higher activity levels, more regression.¹⁵ The exact calorie thresholds from that study are not a universal prescription. For many people, a practical goal is to build toward regular aerobic activity plus resistance training, adjusted to symptoms, fitness, mobility, and clinician guidance.
Build a sustainable dietary pattern, not a search for one plaque-melting food or supplement. In the Lifestyle Heart Trial, a small randomized study, patients followed a very low-fat, plant-forward diet, exercised, practiced stress management, and received group support. After five years, average angiographic narrowing improved in the intensive-lifestyle group and worsened in the usual-care group; cardiac events were also fewer in the intensive group.¹⁶ It was a small study, and it was done before today’s cholesterol medicines were routine. Still, its central message holds: dietary quality, movement, stress management, and social support can be part of meaningful prevention.
An intensive Ornish-style program is one evidence-based model, not the only heart-healthy dietary pattern. Mediterranean-style, plant-forward, high-fiber eating patterns can also support cardiovascular prevention. The best pattern is one that is nutritionally sound and sustainable in the context of your culture, budget, schedule, caregiving responsibilities, symptoms, and preferences.
Treat blood pressure and blood sugar as if they were cholesterol. They feed the same disease process.
Be skeptical of “natural” plaque-reversal promises. No vitamin or supplement has been shown to reliably melt coronary plaque. In HATS, a specific antioxidant-vitamin combination did not add cardiovascular benefit and appeared to attenuate some favorable effects of simvastatin-niacin therapy. That finding does not answer the question for every supplement or every antioxidant formulation.¹⁷
Medication and lifestyle are not competing answers. Sustained lowering of atherogenic particles has the clearest evidence for plaque regression and stabilization, while exercise, dietary quality, smoking cessation, blood-pressure control, glucose management, sleep, and stress support the broader conditions in which cardiovascular risk falls.
When the stress test improves but the blockage does not
This is the part of the story most people have never heard, and it is one of my favorites.
A nuclear stress test does not photograph a blockage. It shows how well blood reaches the heart muscle when the heart is working hard. That can improve for several reasons, and only one of them is a smaller plaque.
In a selected randomized trial of people with stable coronary disease who were eligible for either approach, exercise training was compared with PCI. The trial should not be read as evidence that exercise replaces revascularization when revascularization is clinically indicated. In the exercise group, the narrowing barely changed. Yet blood flow to the heart muscle beyond the narrowing improved, and more people in the exercise group remained free of cardiac events during the year.¹⁸
How? In some people, regular exercise can improve collateral circulation: small alternate channels that may help supply blood beyond a narrowing. In a later trial, four weeks of moderate- or high-intensity exercise increased collateral flow compared with usual care.¹⁹ Better endothelial function in the small vessels, a lower heart rate and blood pressure during exertion, and medicines such as beta-blockers can also improve a stress test.
Improvement on stress imaging is genuinely good news. In a study of combined intensive lifestyle and pharmacologic lipid treatment, participants had fewer perfusion abnormalities and fewer coronary events than those receiving usual-care lipid treatment.²⁰ In the COURAGE nuclear substudy, less residual ischemia on follow-up imaging was associated with better outcomes, although that association weakened after adjustment for other risk factors.²¹ These studies support a useful conclusion: improvement in perfusion matters, but it does not prove that a particular blockage shrank.
Two surprises that can mislead you
Your calcium score may go up on a statin. This worries many patients, and it should not automatically be interpreted as failure. In serial intravascular-imaging studies, statin therapy has been associated with lower overall plaque burden alongside greater calcification within plaque.²² That pattern may reflect a shift in plaque composition, but a rising calcium score by itself cannot tell us whether an individual prevention plan is succeeding or failing. Calcium scoring is not designed to monitor whether treatment is working.
Not every “improved” angiogram is regression. An artery can look narrower or wider depending on its tone at the moment of the picture, whether nitroglycerin was given, the angle of the images, or healing of a prior tear or clot. Before I call a change regression, I compare like with like.
What this means for you
Here is how I approach this with patients:
Know your numbers. That means LDL cholesterol, and sometimes ApoB; Lp(a), measured at least once; A1C or other glucose assessment when appropriate; and home blood-pressure readings. Tell your clinician if you smoke or vape, take hormones, use supplements, or have a history of kidney disease, inflammatory disease, or sleep apnea.
Aim low, and stay there. Regression in trials occurred when LDL-C was lowered substantially and held low over years. Your target depends on your history, disease burden, other risks, tolerance, and personal goals, so it should be set with your clinician.
Think in years, not months. Plaque composition can change within a year. Changes in the channel and in clinical outcomes may take much longer. POSCH needed a decade to show its full picture.⁵
Do not seek repeat invasive procedures simply for a plaque “report card.” Repeat catheterization or other testing should be driven by symptoms, a change in functional status, prior findings, and your clinician’s assessment.
Do not change prescribed treatment based on a scan trend alone. A calcium score, CT plaque measurement, angiogram, or stress test is only one part of the picture. Decisions about antiplatelet therapy, lipid-lowering treatment, blood-pressure medicines, diabetes medicines, exercise intensity, or procedures should be made with the clinician who knows your history.
Keep going, but review the plan. For most people with established coronary atherosclerosis, prevention is long-term. Treatment is not a short course of antibiotics. The specific plan should be reviewed and adjusted for benefit, adverse effects, preferences, pregnancy planning when relevant, and changing circumstances.
The integrative answer
Can your blockages get better? Yes.
But the goal is not to make an angiogram look like a teenager’s. The goal is to reduce the chance that plaque will rupture, improve the blood supply to heart muscle, protect daily function, and prevent the next heart attack.
A recent European scientific statement emphasizes that average plaque-volume changes with treatment are usually limited and that calcified plaque is difficult to reverse.²³ That is true. It is also true that small changes in the right plaques, sustained for years, can translate into large changes in the lives of real people.
Meaningful prevention can begin at many stages of life and disease. The safest starting point depends on your health, symptoms, and current treatment. The medicine and the lifestyle are not competing answers; they are parts of the same long-term plan.
Related reading
This post is for general educational purposes only. It is not medical advice, is not a substitute for care from your own physician, and does not create a physician-patient relationship. Do not start, stop, or change any treatment based on what you read here. If you think you may have a medical emergency, call 911 or go to the nearest emergency department. Full disclaimer at drazhak.com/medical-disclaimer.
Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC. Available now on Kindle. Paperback launches October 20, 2026. Buy on Kindle
© 2026 Cordate Press
References
Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375. https://pubmed.ncbi.nlm.nih.gov/3574413/
Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157–1166. https://pubmed.ncbi.nlm.nih.gov/3180375/
Gotto AM Jr. Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation. 1995;92:646–656. https://pubmed.ncbi.nlm.nih.gov/7634480/
Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298. https://pubmed.ncbi.nlm.nih.gov/2215615/
Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia (POSCH). N Engl J Med. 1990;323:946–955. https://pubmed.ncbi.nlm.nih.gov/2205799/
Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781–1791. https://pubmed.ncbi.nlm.nih.gov/8504494/
Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–1781. https://pubmed.ncbi.nlm.nih.gov/35368058/
Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833–838. https://pubmed.ncbi.nlm.nih.gov/16904557/
Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52:255–262. https://pubmed.ncbi.nlm.nih.gov/18634979/
Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:66–82. https://pubmed.ncbi.nlm.nih.gov/34991791/
Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708–716. https://pubmed.ncbi.nlm.nih.gov/28241355/
Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55:2736–2742. https://pubmed.ncbi.nlm.nih.gov/20538166/
Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565. https://pubmed.ncbi.nlm.nih.gov/16533939/
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384. https://pubmed.ncbi.nlm.nih.gov/27846344/
Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol. 1993;22:468–477. https://pubmed.ncbi.nlm.nih.gov/8335816/
Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001–2007. https://pubmed.ncbi.nlm.nih.gov/9863851/
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease (HATS). N Engl J Med. 2001;345:1583–1592. https://pubmed.ncbi.nlm.nih.gov/11757504/
Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109:1371–1378. https://pubmed.ncbi.nlm.nih.gov/15007010/
Möbius-Winkler S, Uhlemann M, Adams V, et al. Coronary collateral growth induced by physical exercise: results of the EXCITE trial. Circulation. 2016;133:1438–1448. https://pubmed.ncbi.nlm.nih.gov/26979085/
Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol. 2003;41:263–272. https://pubmed.ncbi.nlm.nih.gov/12535820/
Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the COURAGE trial nuclear substudy. Circulation. 2008;117:1283–1291. https://pubmed.ncbi.nlm.nih.gov/18268144/
Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–1282. https://pubmed.ncbi.nlm.nih.gov/25835438/
Conte E, Perone F, Cosyns B, et al. Therapies leading to coronary atherosclerosis plaque regression: a scientific statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy. Part 2: drugs’ specific effect on atherosclerosis. Eur J Prev Cardiol. 2025. doi:10.1093/eurjpc/zwaf654. https://pubmed.ncbi.nlm.nih.gov/41206215/